Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Enanta Pharmaceutica (ENTA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Enanta Pharmaceu Up 37.9% Since SmarTrend Uptrend Call (ENTA)

SmarTrend identified an Uptrend for Enanta Pharmaceu (NASDAQ:ENTA) on January 7th, 2019 at $74.33. In approximately 2 months, Enanta Pharmaceu has returned 37.87% as of today's recent price of $102.48....

ENTA : 103.77 (+1.17%)
Enanta Pharmaceuticals Completes Enrollment in Two Ongoing Phase 2 Studies

--ARGON-1 Study in Non-alcoholic Steatohepatitis (NASH) with EDP-305

ENTA : 103.77 (+1.17%)
Enanta Pharmaceu Rises 1.43% on Heavy Volume: Watch For Potential Pullback

Enanta Pharmaceu (NASDAQ:ENTA) traded in a range yesterday that spanned from a low of $103.21 to a high of $103.54. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high...

ENTA : 103.77 (+1.17%)
Enanta Pharmaceu Up 36.6% Since SmarTrend Uptrend Call (ENTA)

SmarTrend identified an Uptrend for Enanta Pharmaceu (NASDAQ:ENTA) on January 7th, 2019 at $74.33. In approximately 2 months, Enanta Pharmaceu has returned 36.55% as of today's recent price of $101.50....

ENTA : 103.77 (+1.17%)
Uptrend Call Working As Enanta Pharmaceu Stock Rises 37.4% (ENTA)

SmarTrend identified an Uptrend for Enanta Pharmaceu (NASDAQ:ENTA) on January 7th, 2019 at $74.33. In approximately 2 months, Enanta Pharmaceu has returned 37.41% as of today's recent price of $102.14....

ENTA : 103.77 (+1.17%)
AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for its hepatitis C treatment MAVIRET(TM)

AbbVie (NYSE: ABBV), a global, research and development-based biopharmaceutical company, announced an agreement was reached with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding MAVIRETTM (glecaprevir/pibrentasvir...

ENTA : 103.77 (+1.17%)
ABBV : 80.82 (+0.21%)
36.0% Return Seen to Date on SmarTrend Enanta Pharmaceu Call (ENTA)

SmarTrend identified an Uptrend for Enanta Pharmaceu (NASDAQ:ENTA) on January 7th, 2019 at $74.33. In approximately 1 month, Enanta Pharmaceu has returned 36.00% as of today's recent price of $101.09....

ENTA : 103.77 (+1.17%)
Factors of Influence in 2019, Key Indicators and Opportunity within BCE, Nektar Therapeutics, Hormel Foods, Enanta Pharmaceuticals, MongoDB, and Regal Beloit -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of BCE, Inc. (NYSE:BCE), Nektar...

RBC : 82.15 (-0.67%)
HRL : 42.52 (-0.07%)
BCE : 44.30 (-0.18%)
ENTA : 103.77 (+1.17%)
MDB : 138.76 (+0.57%)
NKTR : 34.41 (-1.49%)
Noteworthy Wednesday Option Activity: ENTA, INSM, PPC

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Enanta Pharmaceuticals Inc , where a total volume of 1,646 contracts has been traded...

ENTA : 103.77 (+1.17%)
Enanta Pharmaceu Shares Up 20.9% Since SmarTrend's Buy Recommendation (ENTA)

SmarTrend identified an Uptrend for Enanta Pharmaceu (NASDAQ:ENTA) on January 7th, 2019 at $74.33. In approximately 1 month, Enanta Pharmaceu has returned 20.93% as of today's recent price of $89.89.

ENTA : 103.77 (+1.17%)
Enanta Pharmaceuticals (ENTA) Lags Q1 Earnings and Revenue Estimates

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -14.38% and -4.34%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?...

ENTA : 103.77 (+1.17%)
Enanta Pharmaceuticals: Fiscal 1Q Earnings Snapshot

WATERTOWN, Mass. (AP) _ Enanta Pharmaceuticals Inc. (ENTA) on Wednesday reported fiscal first-quarter net income of $26 million.

ENTA : 103.77 (+1.17%)
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter and Three Months Ended December 31, 2018

--Royalty revenue for the quarter increased to $69.9 million

ENTA : 103.77 (+1.17%)
Enanta Pharmaceuticals (ENTA) Earnings Expected to Grow: Should You Buy?

Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ENTA : 103.77 (+1.17%)
Enanta Pharmaceuticals to Host Conference Call on February 6th at 4:30 pm ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2018

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today...

ENTA : 103.77 (+1.17%)
Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and Business Outlook for 2019 during the 37th Annual J.P. Morgan Healthcare Conference

--Phase 1 clinical study of HBV core inhibitor EDP-514 planned to begin second half of 2019

JPM : 106.80 (-0.36%)
ENTA : 103.77 (+1.17%)
Enanta Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference

SOURCE: Enanta Pharmaceuticals, Inc.">

ENTA : 103.77 (+1.17%)
JPM : 106.80 (-0.36%)
Enanta Pharmaceuticals: Fiscal 4Q Earnings Snapshot

WATERTOWN, Mass. (AP) _ Enanta Pharmaceuticals Inc. (ENTA) on Monday reported fiscal fourth-quarter net income of $27.4 million.

ENTA : 103.77 (+1.17%)
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2018

--Royalty revenue for the quarter increased to $67.2 million

ENTA : 103.77 (+1.17%)
Enanta Pharmaceuticals (ENTA) Expected to Beat Earnings Estimates: Should You Buy?

Enanta Pharmaceuticals (ENTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ENTA : 103.77 (+1.17%)

Van Meerten Stock Picks

Trilogy Metals - Pick of the Day
My Stock Pick of the Day belongs metal mining company Trilogy Metals(TMQ).
TMQ -0.03
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar